- Salarius Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference TranscriptSep 29, 2022
- Q2 2022 Salarius Pharmaceuticals Inc Earnings Call TranscriptAug 08, 2022€35.92 (+6.21%)Earnings
- Q1 2022 Salarius Pharmaceuticals Inc Earnings Call TranscriptMay 12, 2022€47.2 (+31.55%)Earnings
- Q4 2021 Salarius Pharmaceuticals Inc Earnings Call TranscriptMar 10, 2022€70 (+4.17%)Earnings
- Salarius Pharmaceuticals Inc Asset Acquisition Agreement with DeuteRx LLC - M&A Call TranscriptJan 13, 2022
- Q3 2021 Salarius Pharmaceuticals Inc Earnings Call TranscriptNov 04, 2021€144 (+0.70%)Earnings
- Salarius Pharmaceuticals Inc at Benzinga Healthcare Small Cap Conference (Virtual) TranscriptSep 29, 2021
- Q2 2021 Salarius Pharmaceuticals Inc Earnings Call TranscriptAug 05, 2021€136Earnings
- Salarius Pharmaceuticals Inc Virtual KOL & Investor Event Call TranscriptJun 21, 2021
- Q1 2021 Salarius Pharmaceuticals Inc Earnings Call TranscriptMay 12, 2021€194 (+0.52%)Earnings
- Q4 2020 Salarius Pharmaceuticals Inc Earnings Call TranscriptMar 18, 2021€256 (+1.59%)Earnings
- Salarius Pharmaceuticals Inc to Discuss Advancements in the Phase 1/2 Clinical Trial of Seclidemstat Conference Call TranscriptFeb 24, 2021
- Q3 2020 Salarius Pharmaceuticals Inc Earnings Call TranscriptNov 11, 2020€124 (+5.08%)Earnings
- Q2 2020 Salarius Pharmaceuticals Inc Earnings Call TranscriptAug 12, 2020€171 (-11.40%)Earnings
- Q1 2020 Salarius Pharmaceuticals Inc Earnings Call TranscriptMay 14, 2020€152 (+2.01%)Earnings
- Salarius Pharmaceuticals Inc at SNN Network TranscriptNov 20, 2019
Q2 2022 Salarius Pharmaceuticals Inc Earnings Call Transcript
Welcome to the Salarius Pharmaceuticals second-quarter 2022 financial results and business update conference call. All participants will be in listen-only mode. (Operator Instructions) After today's presentation, there will be an opportunity to ask questions. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Kim Golodetz with LHA Investor Relations. Kim, please go ahead.
Thank you. This is Kim Golodetz, Senior Vice President and Principal with LHA Investor Relations. Thank you all for participating in today's call.
Joining me from Salarius Pharmaceuticals are David Arthur, Director and Chief Executive Officer; and Mark Rosenblum, Chief Financial Officer. In addition, Dr. Daniela Santiesteban, Director of Protein Degradation Development, will be available for Q&A.
During this call, Salarius will be making forward-looking statements about operating metrics, future expectations, plans, events, and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)